IQVIA Gets CDSCO Panel Nod To conduct Phase III clinical Study of Lumateperone

Lumateperone is a novel 2nd-generation antipsychotic used to manage both positive and negative symptoms in patients with schizophrenia.

Lumateperone is unique among second-generation antipsychotics based on its target profile and dopamine D2 receptor occupancy. Unlike other antipsychotics, lumateperone has partial agonist activity at presynaptic dopamine (D2) receptors, resulting in reduced presynaptic release of dopamine, and antagonistic activity at postsynaptic dopamine (D2) receptors. These characteristics allow lumateperone to efficiently reduce dopamine signaling.

Lumateperone also targets dopamine (D1) receptors, and a useful secondary result of D1 activation is increased glutamatergic N-methyl-D-aspartate (NMDA) GluN2B receptor phosphorylation. This is significant since NMDA-mediated glutamate signaling appears to be impaired in patients with schizophrenia.

Finally, lumateperone is capable of modulating serotonin by inhibiting serotonin transporters (SERT) and by behaving as a 5-HT2A receptor antagonist.

At the recent SEC meeting for Neurology and Psychiatry held on 12th December 2024, the expert panel reviewed the Phase III clinical study protocol no. ITI-007-421, Amendment 1 dated 15 Mar 2024 (India Amendment #1 dated 24 Oct 2024).

After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm.

Also Read: Conduct Phase III CT: CDSCO Panel Tells Zydus Healthcare on FDC Dextromethorphan, Phenylephrine Syrup